Discovery & the cathelicidin family

• How LL-37 is cut from hCAP-18 and why it is the only human cathelicidin
• How an amphipathic helix disrupts membranes and neutralizes endotoxin
• How LL-37 steers immune cells through FPR2 and drives wound repair
• Where the double-edged risks (hemolysis, inflammation, cancer) really sit

1. 01 Discovery & the cathelicidin family The one antimicrobial peptide your own cells make free
2. 02 Structure: the amphipathic helix How 37 residues fold into a membrane-breaking tool paid
3. 03 Vitamin D induction & regulation What turns the LL-37 gene up and down paid
4. 04 Antimicrobial mechanism How a peptide breaks a bacterium open paid
5. 05 Immunomodulation & chemotaxis The peptide that tells immune cells where to go paid
6. 06 Wound healing & angiogenesis From clearing infection to rebuilding skin paid
7. 07 Antiviral defense & LPS neutralization Against viruses and against the poison of dead bacteria paid
8. 08 Disease associations & the double edge When a protector turns provocateur paid
9. 09 Therapeutic development & delivery Why a promising peptide is so hard to turn into a drug paid
10. 10 Dosing & Administration How LL-37 is handled in research, read critically paid
11. 11 Safety & the double-edged risks What we know about LL-37 risks, and what we do not paid
12. 12 Final Exam & Certification Pass the final exam to earn your specialist certificate. exam

LL-37 was not invented in a lab; it was discovered inside us. Researchers tracing the cathelicidin family found that many mammals carry several of these host-defense peptides, yet humans express just one gene, CAMP. Its product, hCAP-18, is cut by proteases to free the active 37-residue peptide. The timeline below marks how a curiosity of innate immunity became one of the most studied human antimicrobial peptides.

Read the timeline as a widening of scope. LL-37 started as a membrane-punching antibiotic, then turned out to steer immune traffic, heal tissue, and, less happily, feed some autoimmune and tumor processes. That expanding, occasionally contradictory role is exactly why a careful course is worth your time.

Many animals hedge their bets with a whole toolkit of cathelicidins tuned to different threats. Humans took the opposite route and rely on one. That single-peptide strategy makes LL-37 unusually important: it has to cover antibacterial, antiviral, and immune-signaling duties by itself. Comparing the human setup with the multi-peptide animal setup shows why so much pressure rests on this one sequence.

The single-peptide design has a cost: if a pathogen learns to resist LL-37, humans have no backup cathelicidin to switch to. It also means LL-37 must be tightly regulated, because one peptide doing antimicrobial, wound, and immune jobs is one peptide that can misfire in several ways at once.

Strip away the immunology and LL-37 is a short, positively charged chain of 37 amino acids that folds into a helix. A few residue types do most of the work: cationic lysines and arginines give it positive charge, and hydrophobic residues line up on one face. Click through a representative stretch below to see how charge and greasiness alternate along the chain.

That alternation is the whole trick. Because the positive residues cluster on one side and the greasy residues on the other, the folded helix has two faces, one that grips watery, charged bacterial surfaces and one that dives into the oily core of a membrane. Chemistry, not magic, is what lets a 37-residue peptide punch holes in microbes.

Before the mechanisms, here is the honest picture sorted from best supported to missing. Laboratory antimicrobial and immune-signaling data are strong; animal wound and infection models are promising; controlled human clinical outcomes are thin; and long-term safety of LL-37 as a drug is essentially unstudied. Reading these tiers correctly, and refusing to let a lower tier borrow the confidence of a higher one, is the core skill of this course.

A handful of claims dominate online discussion of LL-37, from "natural antibiotic" to "heals any wound." Held against the evidence tiers, most are not flatly false so much as rounded up: a real but narrow finding inflated into a sweeping promise. Tap each claim below to see the honest verdict and where it sits on the evidence ladder.

Notice the pattern across the rows: the further a claim moves from a controlled dish and toward a whole living person, the thinner the evidence gets, and the more LL-37 double-edged nature matters. That is not cynicism, it is how honest reading of a complex peptide works.

Because humans rely on a single cathelicidin, LL-37 wears many hats at once. The hub below spreads its main roles so you can see the full scope before the deep-dive units. Each arm becomes its own unit later: direct microbe killing, immune recruitment, wound repair, antiviral defense, and endotoxin neutralization all trace back to the same cationic, amphipathic helix.

One peptide, five overlapping jobs, is efficient but risky. The same properties that let LL-37 do all of this also let it misfire, driving inflammation in psoriasis or aiding certain cancers. Keep this map in mind: every later unit is one arm of this hub examined in detail, benefits and hazards together.